Drugs / AxV-128/Tc
AxV-128/Tc
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02978144 | Jun 2017 → Oct 2019 | chronic obstructive pulmonary disease | Columbia University | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AxV-128/Tc | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02978144 ↗ |
| Known as | 99mTc-Annexin V-128 | “All study participants will be administered Annexin (study drug also known as 99mTc-Annexin V-128 (AxV-128/Tc)) intravenously (IV) followed by SPECT-CT imaging scan.” NCT02978144 ↗ |
| Known as | Annexin | “All study participants will be administered Annexin (study drug also known as 99mTc-Annexin V-128 (AxV-128/Tc)) intravenously (IV) followed by SPECT-CT imaging scan.” NCT02978144 ↗ |
| Modality | Diagnostic / imaging agent | “Annexin - a radioactive tracer” NCT02978144 ↗ |
| Route | Intravenous | “administered intravenously” NCT02978144 ↗ |